slap it on! topical medications in palliative...
TRANSCRIPT
Paul Daeninck MD, MSc, FRCPCLindsay Lemanski, BSc Pharm
University of Manitoba/CancerCare MBSt. Boniface Hospital
Slap It On!Topical Medications
in Palliative Care
I currently have, or I have had in the past two years, an affiliation with/or financial interests in a business corporation, or I receive remuneration, royalties, or research grants from a business corporation.
Valeant Pharmaceuticals CanadaConsultant
Wyeth PharmaceuticalsConsultant and Advisory Board member
GW Pharmaceutical Clinical Trial Investigator and Advisory Board member
Learning ObjectivesDiscuss the options of using the topical or
transdermal route of drug administrationList indications for use of topical medicationsReview the science and the evidence behind
topical medicationsDiscuss initial clinical use and results
Delivery Routes for MedicationsStandardOralIntravenousInhalation (nebulized)Subcutaneous
AlternativeSublingual
transmucosalmouthwashes
IntranasalTransdermal (topical)RectalVaginalIntraosseus
Reasons for Topical RouteOral route not desirable
MucositisInability to swallowNausea/vomitingGastric/ bowel obstructionPoor taste of product/taste alterations
More localized actionEasily accessibleSystemic adverse effects
Topical Route: AdvantagesAvoids the GI tract and hepatic first-pass
metabolismDelivers to a specific siteControls absorption rateProvides constant dosing depot effect
with anhydrous gelsReduces systemic side effects
Heir G et al. IJPC 2004; 8:337-343
Improves complianceAllows ↑ concentration of Rx at site of
applicationPlasma concentrations of <10% compared
to oral route
Topical Route: Advantages
Heir G et al. IJPC 2004; 8:337-343
Topical Route: DrawbacksVariations in the stratum corneum barrier
Delivery dosing may require adjustmentRate of absorption may vary
Rash most common AECumbersome when using larger areasPatient complianceCost
Heir G et al. IJPC 2004; 8:337-343
Topical RouteOphthalmology
topical meds commonplace
Dermatologylotions, ointments, gels, etc.
Internal medicineblood pressure, pain control, infections, etc.
Gynecologyhormone patches, antibiotic creams
Topical Route
Transdermal RouteFentanyl, scopolamine, estrogen, nitrate patchesTransdermal gels (Pennsaid®)Ointments (Flamazine®)Lotions/creams (steroids or antibiotics)Sunblock (local blockade, ?absorption)
Topical Opioids
Classically, opioids active on CNS receptors mu (μ) kappa (κ) delta (δ) receptorsNow found on:
peripheral neuronsimmune cellsinflamed tissuerespiratory tissueGI tract
Why Topical Opioids?Opioid receptors on peripheral neurons &
dorsal root gangliaInflammation ↑ receptors, activationMacrophages produce opioid peptidesPeptides ↓ neuron excitabilityExogenous opioids ↓ pain, inflammationActivated receptors respond to topical Rx
Stein C. NEJM 1995; 332:1685-1690
Clinical Concerns: Malignant Wounds
PainEmotional stressOdorExudateBleeding Functional compromiseSocial concernsEdemaComplications
21%18%16%11%10%7%6%5%5%
Schulz V et al. JPSM 2002;24 572-77
Chronic Wound InflammationAlters nerves:
excitability, expression of transmitters and receptors
Alters immune system:blood flow, vascular permeability, immune cells, chemicals
Alters spinal processing of pain
Why Topical Opioids?Inflammation ↑ peripheral receptors,
activationMacrophages, lymphocytes produce opioid
peptides (in turn,↓ neuron excitability)Exogenous opioids ↓ pain, inflammationActivated receptors respond to topical Rx
Stein C. NEJM 1995; 332:1685-1690
Topical Opioids: BenefitsSmall doses, little systemic absorptionHigh local concentrationLess side effects↓ constipation, N/V, sedationdecreased risk of toxicityno known drug interactions
Ease of use → better compliance
Twillman R et al. JPSM 1999; 17:288-92Sawynok J.Pharmacol Rev 2003; 55:1-20
Topical OpioidsCase seriesDiamorphine 10 mg in IntraSite® gel
relief in 3 ptsduration 1 wk to 2 mo
Morphine 0.1% in IntraSite® (1 mg/ml )
8/9 reported reliefduration few days to > 1 yr
Back IN & Findlay I. JPSM 1995;10:493Twillman RK et al. JPSM 1999; 17:288-92
Topical OpioidsZylicz et al
Series of papers, 7 patientsMorphine gel (0.08%-0.5%)Pain rapidly ↓ , lasted up to 8 hrsDuration of up to 2 moMinimal side effects
Krajnik M et al. Pain 1999; 80:121-25Krajnik M, Zylicz Z. Pall Med 1997; 11:325-26Krajnik M, Zylicz Z. Prog Pall Care 1997; 5:101-06
Topical OpioidsDiamorphine in IntraSite® gelRCT, double-blind, 13 pts, II/III decubitus ulcersPlacebo x 3/diamorphine (0.1% w:w) x 3; switchPain assess before, 1 h & 12 h after applicationSignificant relief in tx group (n=6) vs placeboA/E: pruritis, skin irritationNo significant systemic effects seen
Flock P. JPSM 2003; 25:547-554
Topical OpioidsMorphine in IntraSite® gelRCT, double-blind, 5 pts, painful sacral ulcersMorphine 10 mg/ml in 8 g IntraSite®
Placebo x 3/morphine x 3 or opposite (2 d w/o)Pain twice daily using VASSignificant relief in tx group vs placeboA/E: pruritis, burning, skin discomfort
Zeppetella G et al. JPSM 2003; 25:555-8
Topical Opioids: BioavailabilityOpen label study, X-over, 6 hospice in-ptsTopical vs SC morphineSerial blood levels post therapyMorphine, M6G, M3G in SC ptsOnly detected 1 topical pt (largest ulcer)No AEs in topical pts, drowsiness in SCTopical opioids act locally, no systemic
absorptionRibeiro MDC et al. JPSM 2004:27:434-39
Topical Opioids: BioavailabilityRCT, X-over, 5 volunteersTopical morphine (10 mg/ml) in PLO 1 ml + SC
placeboTopical placebo + morphine (3mg/ml) 1 ml SC Serial blood levels (16) post therapyMorphine detected in SC samples onlyTopical opioids not systemically absorbed
Paice JA et al. JPSM 2008:35:314-20
Topical OpioidsMethadone in Stomahesive® powderCase series, 4 pts, 3 non-malignant woundsTopical morphine gel not effectiveMethadone 100mg / 10g Stomahesive®
Dry powder worked in open, exudativewounds
Absorption measured via serum levelsEffective in 3 cases, esp. with open wounds
Gallagher R et al. Clin J Pain 2005; 21:190-2pd
Structure of SkinLargest organ of the human bodySkin is composed of 3 primary layers
Epidermis 5 strataDermisHypodermis (Subcutaneous adipose layer)
Structure of Skin
EpidermisStratum Corneum (Horny layer)
Final product of epidermal cell differentiation“Bricks & mortar”Regulates transdermal water loss & prevents
external accessThickness varied
Structure of Skin
EpidermisStratum Corneum (Horny layer)
Final product of epidermal cell differentiation“Bricks & mortar”Regulates transdermal water loss & prevents
external accessThickness varied
Structure of SkinDermis
Major component of skinNetwork of connective tissue Hydrophilic = challenging for lipophillic drugs
Regulation of body temperatureBlood supply maintains [gradient]? “Shunt routes” for early permeation3 main appendages
Williams A. Transdermal and topical drug delivery: from theory to clinical practice, 2003
Structure of Skin
Williams A. Transdermal and topical drug delivery: from theory to clinical practice, 2003
Permeation Pathways(Stratum Corneum)
Transappendageal transportTranscellular routeIntercellular pathwayRelative contributions of these pathways to
the gross flux will depend on the physico-chemical properties of the permeant
Williams A. Transdermal and topical drug delivery: from theory to clinical practice, 2003
Physiological Factors
Physiological factors that influence the rate of drug delivery include:
Skin ageBody SiteEthnicityOther Factors
Williams A. Transdermal and topical drug delivery: from theory to clinical practice, 2003
Other Factors
HydrationSkin water content ~15-20% of tissue
dry weight⇑ water content with occlusion In stratum corneum 25-35 % of water is
‘bound’ within this layer
Williams A. Transdermal and topical drug delivery: from theory to clinical practice, 2003
Other Factors
Williams A. Transdermal and topical drug delivery: from theory to clinical practice, 2003
Liphophilic
Hydrophilic Hydrophilic
Hydrophilic
Factors for Drug Absorption
Physico-Chemical PropertiesSolubility
Lipophilic agents penetrate well across the stratum corneum
Hydrophilic agents absorb better in aqueous layers of the epidermis
Williams A. Transdermal and topical drug delivery: from theory to clinical practice, 2003
Factors for Drug Absorption
Skin CharacteristicsPhysico-Chemical PropertiesChemical Penetration EnhancersVehicle Base
Williams A. Transdermal and topical drug delivery: from theory to clinical practice, 2003
Chemical Penetration Enhancers
Act reversiblyPotencies appear to be drug specificWork well with co-solvents Concentration dependent effectPotential mechanism of action of enhancers
are varied
Williams A. Transdermal and topical drug delivery: from theory to clinical practice, 2003
Finding a Suitable VehiclePassive diffusion into superficial epidermis
sufficient for skin penetration
Drug/vehicle must maintain affinity for aqueous & lipid environments to absorb effectively into systemic circulation
G Harochaw, Personal communication
Vehicles UsedPLO – Pluronic Lecithin Organogel
Pluronic → hydrophilic phaseLecithin Isopropyl Palmitate → lipophilic phase
Wiler’s PCCA
Vehicles Used
Gold StandardPLO
Template VehicleProcess BenefitsStructural/Physical StabilityTopical Delivery PotentialSafety
Kumar R et al. AAPS PharmSciTech 2005; 6:1-47
Vehicles UsedChange PLO Lipoderm
Less chance of rash vs PLOProducts don’t separate as easily Only compounding pharmacies can make
Hydro-Alcoholic GelsDisappears into the skin much faster than PLO Agents used in gel must dissolve completely in
water or alcohol (Not with PLO)
Wiler’s PCCA
Vehicles To Be UsedPenetration rates:
Pentravan,VanPen, PLO 5-20mmPCCA Gel 2058 1-3mmPCCA Gel 4038 10-20mmPCCA Gel 6633 +30mmSpeed Gel up to 50mm
Wiler’s PCCA
Pain PATHWAYPain perception
EnkephalinsEndorphins
BradykininProstaglandins Nitric Oxide
GlutamateAspartateSubstance P
LeukotrienesHistamine
Spinal cord
Descendin
g
Inhibition of Neurotransmitters
Voltage-Gated Na+ Channel Antagonistα2-Adrenoceptor AgonistNE Reuptake InhibitorGlutamate AntagonistNMDA Antagonist
NMDA
Presynaptic Neuron
V-G Na
+
Release
V-G Na
+
Cytoplasm
Postsynaptic
Neuron
AMPAAMPA AMPA
AMPA
DEPOLARIZATION
NMDANMDA NMDA
NMDA
α2 α2
V-G
Ca2+
V-G
Ca2+
μ μ
Ca2+
Ca2+
Mg2+
Ca2+
Ca2+
Glu
Glu
Na+Na+
GluGlu
μ μ
5HTNE
Na+
Voltage-Gated Na+ Channel Antagonist
LidocaineAlters depolarization in neurons by blocking
the voltage gated Na+ channels in the cell membrane
Inhibits depolarization = NO action potential = anesthetic effects
Katzung B Basic & Clinical Pharmacology, 7th ed 1998
NMDA
Presynaptic Neuron
V-G Na
+ V-G Na
+
Cytoplasm
Postsynaptic
Neuron
AMPAAMPA AMPA
AMPA
DEPOLARIZATION
NMDANMDA NMDA
NMDA
α2 α2
V-G
Ca2+
V-G
Ca2+
μ μ
Ca2+
Ca2+
Mg2+
Ca2+
Ca2+
Glu
Glu
Na+Na+
NE5HT
μ μLidocaine
Na+
α2-Adrenoceptor AgonistClonidineSpecificity towards presynaptic α2 receptorsα2 receptors located in peripheral and
central terminals↓ Ca2+ levels = ↓ neurotransmissionLipophilic
Katzung B Basic & Clinical Pharmacology, 7th ed 1998
NE Reuptake InhibitorTricyclic Antidepressants
AmitriptylineInhibition of nociceptive transmission via ↑ in
synaptic NE, 5-HT3
Blockade of α-adrenergic receptors?Anticholinergic effectsExtremely lipophilic
Katzung B Basic & Clinical Pharmacology, 7th ed 1998
NMDA
Presynaptic Neuron
V-G Na
+
Release
V-G Na
+
Cytoplasm
Postsynaptic
Neuron
AMPAAMPA AMPA
AMPA
NMDANMDA NMDA
NMDA
α2 α2
V-G
Ca2+
V-G
Ca2+
μ μ
Ca2+
Ca2+
Mg2+
Ca2+
Ca2+
Glu
Glu
Na+Na+
NE5HT
μ μ
Clon
idine
TCA
Glutamate Antagonist
GabapentinAnalog of gamma-aminobutyric acid
Works via binding to the α2δ subunit of the voltage-gated N-type Ca++ ion channel
Modulates the Ca++ channel & ↓ Ca++ influx↓ presynaptic glutamate release
Davies A et al. Trends Pharmacol Sci 2007;28:220-8Taylor CP. CNS Drug Rev 2004;10:183-188
NMDA AntagonistKetamineN-methyl-D-aspartate antagonist Ionotropic receptor for glutamateBoth ligand-gated & voltage-gatedActivation results in opening of an ion
channelCalcium flux may be critical for synaptic
plasticityKatzung B Basic & Clinical Pharmacology, 7th ed 1998
NMDA
V-G Na
+
Release
V-G Na
+
Cytoplasm
Postsynaptic
Neuron
AMPAAMPA AMPA
AMPA
DEPOLARIZATION
NMDANMDA NMDA
NMDA
α2 α2
V-G
Ca2+
V-G
Ca2+
μ μ
Ca2+
Ca2+
Mg2+
Ca2+
Ca2+
Glu
Glu
Na+Na+
GluGlu
μ μ
Gaba
pent
in
Ketamine
Presynaptic Neuron
General Formulation “Rules”Select a DrugEstimate Drug PenetrationSelect a Vehicle?Role of Chemical Penetration EnhancerBe Realistic
LL
Transdermal DeliveryDrugs listed in percentages
1% Solution = 1000mg/100ml(10mg/ml)
Morphine 1% solutionKetamine 5% in gel
Transdermal Delivery: Meds
Cyclo-oxygenase inhibitor2-10%Diclofenac α2-Adrenoceptor agonist0.1-0.3%ClonidineSubstance P blockade0.025-0.1%CapsaicinGABAβ agonist2-5%BaclofenNE reuptake inhibitor1-5%Amitriptyline
MechanismStrengthDrug
Glutamate antagonist5-10%Gabapentin
Mu (µ) agonist5-10%Loperamide
NMDA-receptor antagonist5-15%KetaminePropionic acid NSAID5-10%KetoprofenAnaesthetic2-10%Lidocaine
MechanismStrengthDrug
Transdermal Delivery: Meds
Transdermal NeuropathicsFour way X-over study, 20 pts c neuropathic pain2 d blinded trial Amitriptyline(A) 1% vs ketamine(K) 0.5% vs
A 1% + K 0.5% vs PLO gelNo relief for any patient11 pts in open label cohort
Topical A 1% + K 0.5% gel applied QID x 7 d
Lynch M et al. Clin J Pain 2003;19:323-28
Significant pain response noted with use of combination gelRash, burning at site in 2 pts No significant systemic absorption of any of the medicationsTopical meds need time to work
Lynch M et al. Clin J Pain 2003;19:323-28
Retrospective, orofacial pain pts (n=39)Systemic Rx, topical, bothTopical (apply 4-6 x daily) contains:
carbamazepine 4% lidocaine 1%ketoprofen 4% ketamine 4%gabapentin 4%
Pain measured baseline and at clinic visitsVAS, 30% reduction = good result
Transdermal Neuropathics
Heir G et al. OOOOE 2008:105:446-9
Best relief with combined therapiesShortest time to relief c topicalsAEs? Standard Rx? doses?Good start for line of researchProspective trials needed
Heir G et al. OOOOE 2008:105:446-9
Pain & Symptom Management Clinic
Multidisciplinary assessment/treatment of pts with symptoms related to cancer or its treatment(s)
Provide consultation, follow-up/evaluation of interventions
Symptoms suitable for clinicReferral from several sources
Pharmacy CollaborationImproved patient outcomes through:
Education of patients/family/allied healthcare membersMonitoring of adverse effectsDrug information/counselingMedication management
Date: __________________________Patient Name__________________________Address: __________________________Date of Birth:__________________________PHIN: __________________________Base: □ Lipoderm □ PLO □ Speed Gel
□ Other (specify) _____________________Check the Ingredient & Strength: Other Strength:Ketamine __5% __10% __15% ______%
(requires a duplicate Rx)Gabapentin __6% __8% __10% ______%Clonidine __0.1% __0.2% ______%Lidocaine __2% __4% __5% ______%Loperamide__5% __10% ______%Ketoprofen __5% __10% __20% ______%Diclofenac __2% __4% __5% ______%Carbamazepine__2% __5% __10% ______%Baclofen __2% __5% ______%Amitriptyline__2% __5% ______%Pentoxifylline__5% __10% __15% ______%Bretylium __1% __2% ______%Nifedipine __2% __5% __10% ______%Camphor __0.25% Menthol __0.5%
Additional Ingredients: ____________________ ______%____________________ ______%
Sig: Apply _____mL to affected area(s)____________(frequency) _______________________.
Mitte: _______mL Refill x _______Physician Name (Print): _______________________________Address: _______________________________Phone: _______________________________Signature: _______________________________
G HarochawD WongP Daeninck
Transdermal Neuropathics
1st combination we use:Ketamine 5-15% Gabapentin 6-8%Lidocaine 2-6%
1st time use success rate ~ 30%Adjust %, add others, add DMSO Success after “fine tuning” gel ~ 70%
G Harochaw, Personal Communication
Clinical ChallengesFollow-up with patients after initial use:If able to contact, can adjust topical to work 70% of
timeIncorrect application (regardless of counselling)
too small an amountapplying to wrong arearubbing too aggressively → creating pain
Poor compound selectionCommunication/compliance issues
physicianspatients
G Harochaw, Personal Communication
Results from ClinicReferrals to P & S clinic13 patients
8 post therapy neuropathy (CT, RT, surgery)4 due to disease (breast ca)1 other (Zoster infection)
Ketamine/lidocaine common to allOther Rx: ketoprofen, gabapentin, loperamidePLO or lipodermTID to QID application
Complete information in 11 ptsAll had some benefit (↓VAS)1 stopped: worsening painAdjustments often improved pain control5 concomitant Rx (opioids, pregabalin)
Compliance may be a problemA/E: nilPts complaints: cost, greasy feeling, inconv.
Results from Clinic
Results from Clinic66 yo male, Stage III Colon, FOLFOX x 12Hands/feet neuropathy (8-9/10 baseline)
Several oral drugs (opioids, TCA, anti-epileptics)
Methadone (6/10 best result)
PLO gel with ketamine 5%, lidocaine 2%, gabapentin 4%, apply TID
Improved 4/10, ↑ gabapentin to 6%Present pain rated as 2/10
Where are we going?Which patients benefit most?Treatment algorithm?
which drugs?which carriers?condition specific?topical alone or with systemic therapy?
Formalize a protocolmeds, follow-up, timing
?Clinical trial
SummaryPts with advanced diseases may require
alternative routes for Rx administrationTopical compounds gaining popularityEvidence for opioids, topicals emergingClinical trial support lackingCollaboration with pharmacy invaluable
ReferencesBack IN, Findlay I. JPSM 1995;10:493Twillman RK et al. JPSM 1999; 17:288-292Krajnik M, Zylicz Z et al. Pain 1999; 80:121-125Krajnik M, Zylicz Z. Palliative Med 1997; 11:325-326Krajnik M, Zylicz Z. Prog Palliative Care 1997; 5:101-106Jepson BA. Lancet 1992;339:503-504Stein C. NEJM 1995; 332:1685-1690Flock P. JPSM 2003; 25:547-554Zeppetella G, Paul J, Ribeiro MDC. JPSM 2003; 25:555-558Heir G et al. IJPC 2004; 8:337-343Schulz V et al. JPSM 2002;24 572-77Sawynok J. Pharmacol Rev 2003; 55:1-20Ribeiro MDC et al. JPSM 2004:27:434-39
ReferencesPaice JA et al. JPSM 2008:35:314-20Gallagher R et al. Clin J Pain 2005;21:190-2Jones M. IJPC 2002; 6:4-6Lynch M et al. Clin J Pain 2003;19:323-28Heir G et al. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:466-9
Valiveti S et al. Intl J of Pharmaceuticals 2004;278:173-80Kumar R et al. AAPS PharmSciTech 2005; 6 (2)Davies A et al. Trends Pharmacol Sci 2007 May;28(5):220-8 Taylor CP. CNS Drug Rev 2004;10:183-188Williams AC. Transdermal and topical drug delivery: from theory to
clinical practice, Pharmaceutical Press, London, 2003Katzung B. Basic & Clinical Pharmacology, 7th ed. 1998